NCT01421589View on ClinicalTrials.gov

Growth Hormone Treatment on Phosphocreatine Recovery in Obesity

NACompletedINTERVENTIONAL

Enrollment

15

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions

ObeseGrowth Hormone Secretion Abnormality

Interventions

DRUG

Growth hormone treatment

Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Massachusetts General Hospital

OTHER